Share Email Print
cover

Proceedings Paper

Extraorally delivered photobiomodulation therapy for prevention of oropharyngeal mucositis in pediatric patients undergoing hematopoietic cell transplantation
Author(s): Christine N. Duncan; Anna N. Yaroslavsky; Wendy B. London; Amy F. Juliano; Stephen T. Sonis; Ather Adnan; Nathaniel S. Treister
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Background: Oral mucositis (OM) is a painful consequence of myeloablative hematopoietic cell transplantation (HCT). Extraorally delivered photobiomodulation therapy (PBMT) is a promising novel intervention for the prevention of OM in children. Objectives: With funding from an NIDCR R34 planning grant, the objectives of this study are 1) to model the dosimetry of external PBMT and the optimal device parameters for the planned clinical trial, and 2) to plan and design a placebo-controlled Phase 2 multicenter clinical trial to determine whether extraorally delivered PBMT can reduce the duration of severe OM in children, with intent for implementation under subsequent U01 funding. Methods: External PBMT dosimetry will be evaluated using pediatric head and neck MRI studies to obtain serial measurements of different tissues that will then be used to develop a sophisticated computational model. We plan to conduct a placebocontrolled Phase 2 multicenter clinical trial in which patients 4 to 21 years of age will be randomized 1:1:1 to receive external PBMT dose 1x, external PBMT dose 2x, or sham PBMT starting from conditioning, daily until day +20 post- HCT. Significance: Extraorally delivered PBMT is a feasible, potentially efficacious intervention that could improve the quality of life for all children undergoing myeloablative HCT. The planned Phase 2 study, based on rigorous dose modeling and with detailed attention to uniform delivery of therapy and OM assessments, will provide critical efficacy data and the potential basis for a subsequent definitive Phase 3 trial. Grant Support: NIDCR R34 DE025908-01

Paper Details

Date Published: 17 February 2017
PDF: 9 pages
Proc. SPIE 10048, Mechanisms of Photobiomodulation Therapy XII, 1004807 (17 February 2017); doi: 10.1117/12.2256528
Show Author Affiliations
Christine N. Duncan, Boston Children's Hospital (United States)
Harvard Medical School (United States)
Anna N. Yaroslavsky, Univ. of Massachusetts Lowell (United States)
Wellman Ctr. for Photomedicine, Massachusetts General Hospital (United States)
Wendy B. London, Boston Children’s Hospital (United States)
Harvard Medical School (United States)
Amy F. Juliano, Massachusetts Eye and Ear Infirmary (United States)
Stephen T. Sonis, Brigham and Women's Hospital (United States)
Harvard School of Dental Medicine (United States)
Biomodels, LLC (United States)
Ather Adnan, Brigham and Women's Hospital (United States)
Nathaniel S. Treister, Brigham and Women's Hospital (United States)
Harvard School of Dental Medicine (United States)


Published in SPIE Proceedings Vol. 10048:
Mechanisms of Photobiomodulation Therapy XII
Michael R. Hamblin; James D. Carroll; Praveen Arany, Editor(s)

© SPIE. Terms of Use
Back to Top